Think of Verquvo as a “Niche” Med for Heart Failure

Reps will tout Verquvo (vericiguat) as a new once-daily add-on for worsening heart failure with reduced ejection fraction (HFrEF).

Verquvo is the first “soluble guanylate cyclase stimulator” for HFrEF. It relaxes blood vessels through the nitric oxide pathway.

Most evidence is in patients already on triple ACEI, ARB, or Entresto (sacubitril/valsartan), beta-blocker (carvedilol, etc), AND aldosterone antagonist (spironolactone, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote